Galanthamine hydrobromide是长效的中心活性的乙酰胆碱酯酶(AChE)抑制剂,IC50为410 nM,同时是神经元烟碱乙酰胆碱受体的变构增强剂。
Galanthamine is an AChE inhibitor with IC50 of 0.35 μM, exhibits 50-fold selectivity against butyryl-cholinesterase.
10 mg/kg缺血后,皮下注射,每天两次或, 3 或6小时,随后间隔12小时,直到牺牲。
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Thomsen T, et al. Eur J Clin Chem Clin Biochem, 1991, 29(8), 487-492.
分子式 C17H22BrNO3 |
分子量 368.27 |
CAS号 1953-04-4 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO <1 mg/mL |
Water 31 mg/mL |
Ethanol <1 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT00566735 | Major Depression|Bipolar Depression|Schizoaffective Disorder | Drug: Razadyne|Drug: Placebo | Massachusetts General Hospital|Ortho-McNeil Janssen Scientific Affairs, LLC | Phase 3 | 2004-07-01 | 2012-11-02 |
NCT00181675 | ADHD | Drug: galantamine HBr | Massachusetts General Hospital | Phase 4 | 2002-12-01 | 2010-07-22 |
NCT00645190 | Alzheimer Disease | Drug: Galantamine HBr | Xian-Janssen Pharmaceutical Ltd. | Phase 3 | 2004-03-01 | 2011-05-18 |
NCT01372306 | Fed | Drug: Reminyl | Dr. Reddy's Laboratories Limited | Phase 1 | 2004-10-01 | 2011-06-29 |
NCT01372280 | Fasting | Drug: Reminyl | Dr. Reddy's Laboratories Limited | Phase 1 | 2004-10-01 | 2011-06-29 |
NCT00416169 | Frontotemporal Dementia|Pick Complex | Drug: galantamine hydrobromide | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 | 2003-05-01 | 2011-06-06 |
NCT00240695 | Cognition Disorder|Nervous System Diseases|Mental Disorders|Brain Diseases | Drug: galantamine hydrobromide | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 2003-05-01 | 2011-05-17 |
NCT00077727 | Schizophrenia | Drug: Extended-release galantamine hydrobromide | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 2003-03-01 | 2011-05-20 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们